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 In the last decade, biological agents have revolutionised 
rheumatology. Tumour necrosis factor- α (TNF α ) neutrali-
sing antibody constructs as infl iximab and adalimumab are 
widely used as treatment for rheumatoid arthritis, ankylosing 
spondylitis, psoriatic arthritis and psoriasis. Infl iximab is a 
chimeric (mouse-human) monoclonal antibody against TNF α . 
It has been shown to induce the formation of human antichime-
ric antibodies. Adalimumab is a fully human antibody against 
TNF α and therefore thought to be less immunogenic than chi-
meric antibodies. However, even fully human antibodies may 
lead to the production of human antihuman antibodies. 
 Unfortunately, despite the overall effectiveness of these 
biological agents, a signifi cant proportion of patients do not 
respond or lose response over time. An explanation may be 
that antibodies are formed against these therapeutic agents. 
Another reason could be the necessity of achieving trough 
anti-TNF α drug concentrations in a target range  (1, 2) . 
 In addition, the incidence of anti-drug antibodies could 
be associated with adverse events. Higher concentrations of 
anti-infl iximab antibodies were associated with a higher risk 
of infusion reactions  (3) , and severe arterial and/or venous 
thromboembolic events have been related with the presence 
of anti-adalimumab antibodies  (4) . 
 Until now, in the absence of direct measurement of drug 
levels and anti-drug antibodies, decision-making in the case 
of failure to anti-TNF α treatment was based on clinical out-
come alone. Recently, a new enzyme linked immunosorbent 
assay (ELISA) has been developed to detect soluble drug 
levels and antibody formation among patients receiving 
infl iximab or adalimumab (Promonitor  ®  , Proteomika, Derio, 
Vizcaya, Spain, distributed by Menarini Diagn o stics S.A.  ®  , 
Badalona, Barcelona, Spain). 
 The aim of this work was to evaluate the analytical perfor-
mance and the clinical validation of these four assays with 
the purpose of testing the hypothesis that they are suitable for 
therapeutic drug monitoring of infl iximab and adalimumab in 
treated patients. 
 Following the recommendations for the optimisation of 
immunoassays  (5) , we performed our evaluation of these 
assays during a period of 6 months and two different reagent 
lots were used. Intra- and inter-assay variability were evalu-
ated on three different days with two replicates of the same 
sample in each assay. The linearity was performed by diluting 
different proportions of a standard from the upper and lower 
end of the dynamic range for each analyte to be evaluated. 
 For the clinical validation study, serum was collected from 
69 patients with rheumatic diseases treated with infl iximab 
(Remicade  ®  , Schering-Plough) or adalimumab (Humira  ®  , 
Abbott Laboratories). Informed consent of the patients was 
required. Before each infusion of infl iximab or subcutane-
ous injection of adalimumab, 10 mL of serum was collected 
and stored at  – 20 ° C. All sera were tested under standardised 
conditions specifi ed by the fabricant. Six dilutions of serum 
samples and 10 for each standard curve were made. All the 
analytical development was carried out without knowledge 
of clinical data. 
 Briefl y, in the anti-TNF α drug assay, recombinant human 
TNF α was coated overnight at room temperature on the solid 
phase and recognised by infl iximab or adalimumab in each 
case. The therapeutic monoclonal antibody was detected by 
an anti-human inmunoglobulin specifi c antibody conjugated 
to biotine. Serum concentrations of antibodies against these 
drugs were measured using a double-antigen ELISA based on 
their capture by drug-coated microplates and their detection 
by biotine-coupled anti-TNF α drug. 
 This ELISA has a detection limit of 2 ng/mL for infl i ximab 
and 0.4 ng/mL for adalimumab. And the cut-off value for the 
drug is 0.053 mg/L for infl iximab and 0.002 mg/L for adali-
mumab. And for antibodies, the cut-off value is 37 UA/mL for 
infl iximab and 8 UA/mL for adalimumab. 
 Descriptive statistics were provided using median (range) 
or percentages. Statistical analysis was performed using the 
Sigma Plot  ®  program. Differences between independent 
groups were traced with the use of Student t-test for nor-
mally distributed values. p-Values  < 0.05 were considered 
statistically signifi cant. 
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 Within-run CVs ranged from 7.2 % to 9.5 % . Between-day 
imprecision ranged from 11.9 % to 13.7 % . The regression 
analyses of the data for the linearity studies showed correlation 
coeffi cients from 0.990 to 0.993. 
 A total of 23 serum samples from 21 infl iximab-treated 
patients (mean age 54.4 ± 14.3, 10 males, 11 females), and 54 
serum samples from 48 adalimumab-treated patients (mean 
age 51.4 ± 15.8, 11 males, 37 females) were tested in the 
clinical validation study. 
 All the patients who developed antibodies against infl i-
ximab (n = 3, 14.3 % ) or adalimumab (n = 5, 10.4 % ) in our study 
had trough serum concentration below the limit of detection 
of each assay. In these patients, median concentration of anti-
drug antibodies were 1282 UA/mL (range 558 – 187,000) for 
infl iximab and 4372 UA/mL (132 – 717,824) for adalimumab. 
 In the others, median trough-free levels of infl iximab or 
adalimumab were 11.2 (3.6 – 73.2) mg/L and 6.6 (0.1 – 21.3) 
mg/L, respectively. The patients with anti-drug antibodies 
had signifi cantly lower mean trough serum concentration 
(p < 0.05). 
 These results correlate well with the clinical fi ndings: 
patients ’ responders have absence of anti-drug antibodies and 
signifi cantly higher serum concentrations of the drug than 
non-responders  (6) . 
 Two adalimumab treated patients showed undetectable drug 
concentration without anti-adalimumab antibodies, refl ecting 
therapeutic non-compliance that was confi rmed later, by ask-
ing the patient. 
 Therapeutic drug monitoring is the optimal way to achieve 
effective treatment when drugs with interindividual variabi-
lity are used, such as anti-TNF α drugs. These drugs work best 
over a small blood concentration range. Below this range, 
serum anti-TNF α drug concentrations were probably too low 
to have a therapeutic effect. And above this range, to prevent 
adverse reactions, dose reduction or interval extension might 
be possible without the loss of clinical response. Taking into 
account the high cost of these drugs, it might be more cost-
effective to adjust anti-TNF α drug dosages according to 
serum drug concentrations  (2, 7, 8) . 
 Furthermore, one of the mechanisms of response failure 
is associated with low trough levels of anti-TNF α biologi-
cal agents consequence of development of antibodies against 
these drugs  (2) . Moreover, patients who had developed anti-
drug antibodies against their fi rst TNF α inhibitor had a clini-
cal response to their second TNF α inhibitor that did not differ 
from TNF α -naive patients. This also suggests that patients 
who do not respond to a TNF α inhibitor, despite adequate 
serum drug levels and the absence of anti-drug antibodies, 
are likely to benefi t more from a therapy based on another 
mechanism of action than from another TNF α inhibitor yet 
again  (9) . 
 We evaluated four assays for the detection of infl iximab, 
adalimumab and specifi c antibodies to each drug, and analy-
sed the serum samples of patients treated with these drugs 
to investigate the relationship between serum drug levels and 
antibody formation. The assays exhibited sensitivity, preci-
sion, recovery and reproducibility suitable for the intended 
purpose of the assays  (5) . 
 Although differences in assays and diverse patient popula-
tions studied make a direct comparison diffi cult, our results 
are similar to those reported of previous studies, which have 
suggested that antibodies against infl iximab or adalimumab 
are found in 19 % – 51 % or 17 % – 29 % of patients receiving 
these drugs, respectively  (1, 2, 8, 10) . As we can expect, of 
these two monoclonal antibodies, adalimumab appears to be 
less immunogenic that infl iximab. Patients with antibodies 
had lower serum anti-TNF α drug concentrations than with-
out antibodies showing that the presence of antibodies led to 
more rapid elimination of the drugs via the formation of drug-
anti-drug immune complexes  (9) . 
 It should be taken into account that circulating drug can 
interfere with the detection of anti-drug antibodies, therefore 
impairing the sensitivity of the anti-drug antibodies assays. 
However, the clinical relevance in patient monitoring is ques-
tionable since antibodies will be likely detected in the fol-
lowing test, since it is expected that the antibody titre will 
increase over the drug amount. However, this phenomenon 
is not clinically relevant for the detection of the drug in the 
presence of anti-drug antibodies, because when a patient is 
reported as antibody-positive, this implies that either the drug 
is complexed to antibodies and cannot be measured, or that 
there is no drug present.  Regardless of this, the drug is com-
pletely ineffective. 
 In conclusion, our studies indicate that these infl iximab and 
adalimumab Promonitor  ®  ELISA performed well in terms of 
precision, linearity and clinical evaluation. With the disponibi-
lity of this new commercial available kit, the best blood level 
range for each drug must be found to be used as a kind of 
therapeutic target, to take adequate therapeutical decisions or 
adjustments, or to design patient-specifi c treatment programs. 
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